

ProtoKinetix, Inc.  
Form 10QSB/A  
April 30, 2008

U. S. SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 10-QSB/A

QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2006

TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission File Number: 0-32917

PROTOKINETIX, INC.

Nevada	94-3355026
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

Suite 1500-885 West Georgia Street  
Vancouver, British Columbia Canada V6C3E

\_\_\_\_\_  
(Address of principal executive offices, including zip code)

Registrant's telephone number, including area code:  
(604) 687-9887

Securities registered pursuant to Section 12(b) of the  
Act:

None

Securities registered pursuant to Section 12(g) of the  
Act:

\$.0000053 par value common stock

Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by a check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  
Yes  No

APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY  
PROCEEDINGS DURING THE PRECEDING FIVE YEARS

Edgar Filing: ProtoKinetix, Inc. - Form 10QSB/A

Check whether the registrant filed all documents and reports required to be filed by Section 12, 13, or 15(d) of the Exchange Act of 1934 after the distribution of securities under a plan confirmed by a court. Yes \_\_\_ No \_\_\_

APPLICABLE ONLY TO CORPORATE ISSUERS

State the number of shares outstanding of each of the issuer's classes of common equity, as of the latest practicable date:

41,496,835 common shares outstanding, \$0.0000053 par value, at May 8, 2006.

Transitional Small Business Disclosure Format: Yes \_\_\_ No X

This Form 10-QSB/A This form 10-QSB/A for the period ended March 31, 2006 is being filed in order to amend incorrect financial statements on form 10-QSB for the period ending March 31, 2006.

---

PART I

ITEM 1. FINANCIAL STATEMENTS

Our Financial Statements are attached on Pages F1 – F5.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OR PLAN OF OPERATIONS

FORWARD-LOOKING STATEMENTS

The information in this Quarterly Report on Form 10-QSB contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements involve risks and uncertainties, including statements regarding our capital needs, business plans, and expectations. These risks and uncertainties could cause actual results to differ materially from those expressed in forward-looking statements. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance. Forward-looking statements are only predictions. The forward-looking events discussed in this Quarterly Report, the documents to which we refer you, and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. For these statements, we claim the protection of the “bespeaks caution” doctrine. The forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation to publicly release the results of any revisions to these forward-looking statements to reflect events or circumstances after the date of this filing.

Critical Accounting Policies

Our critical and significant accounting policies, including the assumptions and judgments underlying them, are disclosed in the Notes to the Financial Statements. These policies have been consistently applied in all material respects and address such matters as revenue recognition and depreciation methods. The preparation of the financial statements in conformity with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reported period. Actual results could differ from those estimates. The accounting treatment of a particular transaction is specifically dictated by accounting principles, generally accepted in the United States of America, with no need for management’s judgment in their application. There are also areas in which management’s judgment in selecting any viable alternative would not produce a materially different result. See our audited financial statements and notes thereto which contain accounting policies and other disclosures required by accounting principles, generally accepted in the United States of America.

Overview

We are a biotechnical company headquartered in Vancouver, British Columbia that owns the world-wide rights to a family of synthetic anti-freeze glycoproteins (trademarked by us as AAGP™). We are dedicated to the commercial development of AAGP™ for use in human and veterinary medicine, food additives and supplements, and the biotechnology and cosmetic industry. We are making rapid and meaningful progress in this domain by coordinating a team of world recognized intellectual talent in a networked environment. This team has been able to use previously

published research on native antifreeze proteins and antifreeze glycoproteins as a guide to the expansion and development of markets for this valuable family of molecules.

The ProtoKinetix business plan is based primarily on the furtherance of certain intellectual property rights obtained by way of "sub-licenses" of technology from other companies. At present, although we have engaged the prestigious patent law firm of Cabinet-Moutard of Versailles, France, to file a number of international patent applications (consistent with our agreements with the licensors of various technologies we license), we have no finished commercial product or products, and have received no final patents awards or FDA approvals for any product or diagnostic procedures. We are focused on the research and development of one primary compound known as AFGP, which we have filed a trademark application for.

#### Employees

We currently have no full time employees. We operate with a skeletal management team headed by John Todd, M.D. In addition to Dr. Todd, we receive advice and counsel from our Scientific Advisory Board.

#### Our Main Project

We are currently developing and testing synthetic antifreeze glycoproteins (AFGP). ProtoKinetix has entered into agreements to acquire the exclusive right to develop products derived from patent pending technologies related to synthetic AFGPs. Our intellectual property rights were developed by Dr. Jean-Charles Quirion.

#### Background on our AFGP Project

One of many accomplishments from pioneering research of the U.S. Antarctic Program was the discovery, in the early sixties, that fish living year-long in subzero temperature are extremely resistant to freezing. The substances that prevent these fish from freezing were isolated, characterized and designated as antifreeze glycoproteins or AFGP. Over the years, various kinds of AFGP were isolated from many species of fishes, and in some amphibians, plants and insects. All of the AFGPs share a common characteristic that prevents ice crystals from growing and connecting to each other.

A review of the scientific literature will confirm that there has been a great deal of interest around the world in these natural antifreeze glycoproteins which are able to protect a great many creatures which are subjected to freezing temperatures. A further review will also confirm that the natural antifreeze is able to preserve mammalian cells tissue and organs. The metabolic rate in living cells is reduced as the temperature is lowered. Keeping cells and tissue at a low temperature enables their preservation for a longer time than cells can be preserved for at a higher temperature. Yet, when cells are exposed to sub zero temperatures, they are destroyed by the formation of ice crystals which disrupts the cell membrane.

Scientists have conducted many experiments in which they extracted naturally occurring AFGP from a variety of fish and then used these naturally occurring antifreeze glycoproteins to reduce the temperature at which ice crystals are formed. It has been determined in experiments by many scientists that mammalian cells in a solution containing natural AFGP could be successfully preserved at temperatures several degrees below zero Celsius. At this temperature the metabolic rate of the cells is very low, and these cells can be preserved for a longer period of time at sub zero temperatures as long as the cells are not destroyed by the formation of ice crystals. However, until today, applications of AFGP were limited since researchers were unable to produce sufficient quantities or stable enough copies of these antifreeze glycoproteins for commercial applications, and the use of naturally occurring compounds extracted from fish is too labor and cost-intensive to be practical.

Researchers, headed by Dr. Jean Charles Quirion in Rouen, France have developed an innovative and patented chemical synthesis protocol for manufacturing and stabilizing AFGP molecules using a chemical bond that protects

these compounds from degradation by naturally occurring enzymes. Dr. Quirion and his team have produced several synthetic antifreeze glycoproteins and have the ability to produce many more different types of these molecules. The synthetic AFGP which has been made has been tested and we were able to show:

- The molecules are stable down to a pH of 1.8
- There is no toxicity demonstrated in 2 separate trials
- The molecules tested have shown that they reduce the freezing point to minus 18 degrees Celcius
- We have been able to preserve red cells at temperatures below zero Celcius using 1 mg per ml of the synthetic antifreeze

Current research is being conducted to confirm the efficacy of these chemically synthesized new molecules and applications are being sought for the use of the synthetic AFGP to prolong the shelf-life of human blood and blood products as well as for other cell types, live vaccines, tissue and organs. The market for the preservation of blood and blood products is very large, as is the market for the preservation of human and animal cells for research purposes. The subzero cryopreservation of organs using our synthetic AFGP will be a major milestone in transplantation medicine

ProtoKinetix will continue to conduct research on the synthetic AFGP which are being manufactured. This work will be conducted by government agencies as well as by contract with private laboratory facilities.

#### Intellectual Property

As of the date of this Report, although our development agents, including the parties we have licensed AFGP technologies from, have applied to receive patents for technologies ProtoKinetix has licensed and continues to primarily base it's research efforts on, no patents have issued by a governmental or quasi-governmental agency. The references of applications that we have filed to date are PCT/IB2005/003940, filed on December 2, 2005 under the priority of the French patent application FR 0412782 which was filed on December 2, 2004.

Subject to our available financial resources, our intellectual property strategy is: (1) to pursue licenses, trade secrets, and know-how within our primary research areas, and (2) to develop and acquire proprietary positions to reagents and new platforms for the development of products related to these technologies.

#### Trade Secrets and Know-How

We believe that even if our intellectual property position is ultimately diminished as a result of our development agents and licensors to receive patent protection for the licenses ProtoKinetix has contracted to access, we have developed a substantial body of trade secrets and know-how relating to the development of AAGP™, including but not limited to the optimization of materials for efforts, and how to maximize sensitivity, speed-to-result, specificity, stability and reproducibility.

#### Competition

The markets that we are attempting to enter are multi-billion dollar international industries. They are intensely competitive. Many of our competitors (from every perspective) are substantially larger and have greater financial, research, manufacturing, and marketing resources.

Industry competition in general is based on the following:

- Scientific and technological capability;
  - Proprietary know-how;
- The ability to develop and market products and processes;

## Edgar Filing: ProtoKinetix, Inc. - Form 10QSB/A

- The ability to obtain FDA or other required regulatory approvals;
- The ability to manufacture products that meet applicable FDA requirements, (i.e. FDA's Quality System Regulations) see Governmental Regulation section;
  - Access to adequate capital;
  - The ability to attract and retain qualified personnel; and
    - The availability of patent protection.

We believe our scientific and technological capabilities are significant. Some of the results of our research are available at our website located at [www.protokinetix.com](http://www.protokinetix.com).

Our ability to develop our research is in large measure dependent on our having additional resources and/or collaborative relationships, particularly where we can have our product development efforts funded on a project or milestone basis. We believe that our know-how with our AFGP project, in spite of not yet receiving any patent protected rights, has been instrumental in our obtaining the collaborations we have developed.

Although there is no such immediate need to make any regulatory filing in the United States or abroad, you should be aware that we have limited experience with regard to obtaining FDA or other required regulatory approvals, and no experience with obtaining pre-marketing approval of a biologic product. For this reason, should our research efforts continue to show promise, we will likely need to hire consultants to assist us with such governmental regulations.

Our access to capital is more challenging, relative to most of our competitors. This is a competitive disadvantage. We believe, however, that our access to capital may increase as we get closer to the development of a commercially viable product.

To date, we believe our research has enabled us to attract and retain qualified consultants. Because of the greater financial resources of many of our competitors, we may not be able to complete effectively for the same individuals to the extent that a competitor uses its substantial resources to attract any such individuals.

As is discussed above, with respect to the availability of patent protection, we do not have our own portfolio of patents or the financial resources to develop and/or acquire a portfolio of patents similar to those of our larger competitors. We have been able to obtain access to patent-pending technology by entering into licensing arrangements. However, there can be no certainty that any of the patent-pending technologies we have licensed will ever receive final approval by any patent office.

### Plan of Operation

Our current operations are centered around our relationships with various research and development consultants who are conducting research on our behalf at discrete and established laboratories in various parts of the world. We intend to continue these efforts for the next 12 months and believe, that due to our relatively minimal cash obligations, that we can satisfy our cash requirements during this period. We intend to help meet our corporate obligations by selling our common stock. However our common stock is at a low price and is not actively traded.

### Sales and Marketing

We are not currently selling or marketing any products.

### Expenses

Expenses for the period ending March 31, 2006 arose primarily from professional and consulting fees. We incurred professional fees relating to costs associated with our being a reporting company under the Securities Exchange Act of 1934, as amended. We also incurred consulting fees which contributed to a net loss of \$215,046 during the three

month period ended March 31, 2006.

#### Liquidity and Capital Resources

At March 31, 2006, we had \$451,205 in cash and \$485,554 in total current assets. As of the date of this report, we do not believe that we require additional capital investments or borrowed funds to meet cash flow projections and carry forward our business objectives. In the event that we need to raise additional capital, there can be no assurance that we will be able to raise capital from outside sources in sufficient amounts to fund our new business.

The failure to secure adequate outside funding would have an adverse affect on our plan of operation and results therefrom and a corresponding negative impact on shareholder liquidity.

#### Inflation

Although management expects that our operations will be influenced by general economic conditions, we do not believe that inflation had a material effect on our results of operations for the period ending March 31, 2006.

#### Going Concern

The accompanying financial statements have been prepared in conformity with generally accepted accounting principles, which contemplate our continuation as a going concern. The history of losses and our inability to make a profit from selling a good or service has raised substantial doubt about our ability to continue as a going concern.

#### Results of Operations for the Period Ending March 31, 2006

We had \$0 in net revenues.

We had a \$215,046 loss from operations for the Period Ending March 31, 2006.

Operating expenses were \$215,046 for the period ending March 31, 2006. These expenses were primarily incurred for professional fees, consulting services related to the operations of the Company's business, specifically, research and development related expenses, and other general and administrative expenses.

### ITEM 3. CONTROLS AND PROCEDURES

As required by Rule 13a-15 under the Securities Exchange Act of 1934 ("Exchange Act") we carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of March 31, 2006, being the date of our most recently completed fiscal quarter. This evaluation was carried out under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer. Based upon that evaluation, they concluded that our disclosure controls and procedures are effective to ensure that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized, and reported within the time periods specified in the Securities and Exchange Commission's rules and forms, and that such information is accumulated and communicated to them to allow timely decisions regarding required disclosure.

During our most recently completed quarter ended March 31, 2006, there were no changes in our internal control over financial reporting that have materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.





PART II

ITEM 1. LEGAL PROCEEDINGS

We are not party to any legal proceedings and to our knowledge, no such proceedings are threatened or contemplated against us.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

We did not complete any sales of securities without registration under the Securities Act of 1933 during our first quarter ended March 31, 2006.

ITEM 3. DEFAULT UPON SENIOR SECURITIES

None

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

No matters were submitted to our security holders for a vote during our first quarter ended March 31, 2006.

ITEM 5. OTHER INFORMATION

None

ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K.

Ex. #	Description
3(i).1	Certificate of Incorporation filed as an exhibit to the Company's registration statement on Form 10SB/A filed on July 24, 2001 and incorporated herein by reference.
3(ii).1	By-Laws filed as an exhibit to the Company's registration statement on Form 10SB/A filed on July 24, 2001 and incorporated herein by reference.
14.1	ProtoKinetix, Inc. Code of Ethics file as an exhibit to our annual report on Form 10-KSB filed on April 13, 2006.
23.1	Consent of Peterson Sullivan PLLC
31.1	Rule 13a-12(a)/15d-14(a) Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 302 the Sarbanes-Oxley Act of 2002.
32.1	Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act

of 2002.

---

Signatures

In accordance with Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant caused this report, for the period ended March 31, 2006 to be signed on its behalf by the undersigned, thereunto duly authorized.

Protokinetix, Inc.

/s/ Ross Senior

\_\_\_\_\_  
By: Ross Senior

Its: President, CEO and CFO

In accordance with the requirements of the Exchange Act, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Signatures	Title	Date
/s/Ross Senior Ross Senior	President, CEO and Chief Financial Officer	April 30, 2008

PROTOKINETIX, INC.

Balance Sheet at March 31, 2006

Statements of Operations for the three months ended March 31,  
2006 and 2005 and

for the Period from December 23, 1999  
(Date of Inception) to March 31, 2006

Statements of Stockholder's Equity for the Period from December 23, 1999  
(Date of Inception) to March 31, 2006

Statements of Cash Flows for the three months ended March 31,  
2006 and 2005 and

for the Period from December 23, 1999  
(Date of Inception) to March 31, 2006

Notes to Financial Statements

PROTOKINETIX, INC.	
(a Development Stage Company)	
BALANCE SHEET	
March 31, 2006	
(Unaudited)	
(Restated)	
<b>ASSETS</b>	
Current Asset, as restated	
Cash	\$ 451,205
Accounts receivable	34,149
Prepaid expenses	200
Total current assets	485,554
Computer equipment, net	2,206
	\$ 487,760
<b>LIABILITIES AND STOCKHOLDERS' EQUITY</b>	
Current Liabilities	
Due to outside management consultants	\$ 306,892
Accounts payable	122,406
Accrued interest	38,760
Total current liabilities	468,058
Convertible Note Payable	123,323
Total liabilities	591,381
Stockholders' Equity	
Common stock, \$.0000053 par value; 100,000,000 common	
shares authorized; 40,967,556 shares i s s u e d a n d outstanding	221
Common stock issuable; 1,420,000 shares	8
Additional paid-in capital	15,000,326
	(15,104,176)

Edgar Filing: ProtoKinetix, Inc. - Form 10QSB/A

Deficit accumulated during the development stage, as restated

	(103,621)
	\$ 487,760

See Notes to Financial Statements

PROTOKINETIX, INCORPORATED			
(A Development Stage Company)			
STATEMENTS OF OPERATIONS			
For the Three Months Ended March 31, 2006 and 2005, and for the			
Period from December 23, 1999 (Date of Inception) to March 31, 2006			
(Unaudited)			
(Restated)			
	Three Months Ended March 31, 2006	Three Months Ended March 31, 2005	Cumulative During the Development Stage
Revenues	\$ -	\$ -	\$ 2,000
General and administrative expenses			
Licenses, as restated			3,379,756
Professional fees	102,025	75,690	2,528,718
Consulting fees	31,500	11,476	8,069,179
R e s e a r c h a n d development	37,063	142,802	657,245
G e n e r a l a n d administrative	41,992	52,411	389,053
Interest	2,466	5,728	38,759
	215,046	288,107	15,062,710
Loss from continuing operations	(215,046)	(288,107)	(15,060,710)
Discontinued Operations			
Loss from operations of the discontinued segment	-	-	(43,466)
Net loss	\$ (215,046)	\$ (288,107)	\$ (15,104,176)
Net Loss per Share (basic and fully diluted)			
Continuing operations	\$ (0.01)	\$ (0.01)	
Discontinued operations	(0.00)	(0.00)	
Net loss per common share	\$ (0.01)	\$ (0.01)	
Weighted average number of common shares outstanding	42,019,236	35,948,798	

See Notes to Financial Statements

---



**PROTOKINETIX, INCORPORATED**

(A Development Stage Company)

**STATEMENTS OF STOCKHOLDERS' EQUITY**

For the Three Months Ended March 31, 2006, and for the Period From

December 23, 1999 (Date of Inception) to March 31, 2006

(Unaudited)

	Common Stock		Common Stock Issuable		Additional Paid-in Capital	Deficit Accumulated Stock Subscriptions Receivable	Deficit Accumulated During the Development Stage
	Shares	Amount	Shares	Amount			
Issue of common stock, December 1999	9,375,000	\$ 50	-	\$ -	\$ 4,950	\$ -	\$ -
Net loss for period							(35)
Balance, December 31, 2000	9,375,000	50	-	-	4,950		(35)
Issue of common stock, April 2001	5,718,750	30			15,220		
Net loss for year							(16,902)
Balance, December 31, 2001	15,093,750	80	-	-	20,170		(16,937)
Net loss for							(14,878)

Edgar Filing: ProtoKinetix, Inc. - Form 10QSB/A

year								
Balance, December								
31, 2002	15,093,750	80	-	-	20,170		(31,815)	(
Issue of common stock for services:								
July								
2003	2,125,000	11			424,989			
August								
2003	300,000	2			14,998			
September								
2003	1,000,000	5			49,995			
Other								
2003	1,550,000	8			619,992			
Issue of common stock for exercising rights								
Common stock issued for exercising rights								
Shares exercised on September								
30, 2003	(9,325,000)	(49)			49			
Net loss for year, as restated							(3,662,745)	(3,6
Balance, December								
31, 2003	24,743,750	131	2,000,000	11	3,530,108	-	3,694,560)	(1
Issue of common								

Edgar Filing: ProtoKinetix, Inc. - Form 10QSB/A

stock  
for  
services:

<del>Min</del> 2004	1,652,300	9	991,371
<del>May</del> 2004	500,000	3	514,997
<del>July</del> 2004	159,756	1	119,694
<del>Aug</del> 2004	100,000	1	70,999
<del>Other</del> 2004	732,400	4	479,996
<del>Nov</del> 2004	650,000	4	454,996
<del>Dec</del> 2004	255,000	1	164,425

~~Common~~  
stock  
issuable  
for  
AFGP  
license

1,000,000 5 709,995

~~Common~~  
stock  
issuable  
for  
Recaf  
License

400,000 2 223,998

~~Warrants~~  
granted  
(for  
~~35,000~~  
shares)  
for  
services,

~~Other~~  
2004 1,716,253

~~Options~~  
granted  
for  
services,  
~~Other~~  
2004

212,734

~~Stock~~  
options  
receivable

1,800,000 10 329,990 (330,000)

~~Warrants~~  
exercised:

~~Aug~~  
2004 50,000 15,000

Edgar Filing: ProtoKinetix, Inc. - Form 10QSB/A

Other									
2004			600,000		3		134,997		
Debt									
2004			1,000,000		5		224,995		
Options									
exercised,									
Debt									
2004			100,000		1		29,999		
Net									
loss									
for									
period								-	(6,368,030)
Balance,									(6,368,030)
Debt									
31,									
2004	28,793,206	\$	154	6,950,000	\$	37	\$	9,924,547	\$
								(330,000)	\$
									(10,062,590)
									\$
									(4,368,030)

Issue									
of									
stock									
subscriptions									
receivable								240,000	
Issue									
of									
common									
stock									
for									
exercising									
rights	2,000,000		11	(2,000,000)		(11)			
Issue									
of									
stock									
for									
wards									
exercised	2,050,000		10	(2,050,000)		(10)			
Options									
exercised,									
Debt									
2005				35,000		1		10,499	
Debt									
2005	200,000		1					59,999	
Note									
payable									
containing									
Debt									
2005				285,832		1		85,749	
Issue									
of									
common									

stock  
for  
Note  
payable  
conversion

April 2005	285,832	1	(285,832)	(1)	
May 2005	353,090	2			105,925
Issue of common stock for AFGP license	1,000,000	5	(1,000,000)	(5)	
Issue of common stock for stock subscriptions received	1,400,000	6	(1,400,000)	(6)	90,000
Issue of stock for options exercised	135,000	2	(135,000)	(2)	
Issue of common stock for services:					
April 2005	30,000	1			14,999
May 2005	3,075,000	15			3,320,985
June 2005	50,000	1			50,499
Aug 2005	(250,000)	(1)			(257,499)
Aug 2005	111,111	1	(92,593)	(1)	15,000
Other 2005	36,233	1	(36,233)	(1)	-
Nov 2005	311,725	2	(245,000)	(1)	36,249

~~Net~~  
2005

~~Debt~~  
2005

1,220,000

8

756,392

~~Common~~  
stock  
issuable  
for  
services  
rendered

~~June~~  
2005

200,000

1

149,999

~~Aug~~  
2005

36,233

1

21,739

~~Sept~~  
2005

125,000

1

74,999

~~Sept~~  
2005(Proteocell)

100,000

1

57,999

~~Debt~~  
2005

120,968

1

74,999

Net  
loss  
for  
the  
year

(4,826,540)

(4,8

~~Balance,~~  
~~Debt~~

31,  
2005

40,801,197 \$ 220

608,375 \$ 6 \$

14,503,079 \$

- \$ (14,889,130) \$

(

~~Common~~  
stock  
issuable:

~~February~~  
~~2006~~

placement

900,000

2

352,145

~~May~~  
2006

services

20,000

1

10,499

~~Warrants~~  
granted  
from  
private  
placement  
(450,000)

97,853

~~Issue~~  
of  
common

stock  
for  
services:

Mar 2006	166,359	1	(108,375)	(1)	36,750			(215,046)	(2)
-------------	---------	---	-----------	-----	--------	--	--	-----------	-----

Mar 31, 2006	40,967,556	\$ 221	1,420,000	\$ 8	\$ 15,000,326	\$	-	\$ (15,104,176)	\$ (1)
--------------------	------------	--------	-----------	------	---------------	----	---	-----------------	--------

See Notes to Financial Statements

PROTOKINETIX, INCORPORATED			
(A Development Stage Company)			
STATEMENTS OF CASH FLOWS			
For the Three Months Ended March 31, 2006 and 2005, and for the Period From			
December 23, 1999 (Date of Inception) to March 31, 2006			
(Unaudited)			
	Three Months Ended March 31, 2006	Three Months Ended March 31, 2005	Cumulative During the Development Stage
<b>Cash Flows from Operating Activities</b>			
Net loss for period, as restated	\$ (215,046)	\$ (288,107)	\$ (15,104,176)
Adjustments to reconcile net loss to net cash flows provided by (used in) operating activities			
Depreciation expense	255	126	1,182
<b>Issuance of common stock for services and expenses, as restated</b>			
	47,250	-	11,604,141
Warrants issued for consulting services	-	-	1,716,253
Stock options issued for consulting services	-	-	212,734
<b>Changes in operating assets and liabilities</b>			
Accounts receivable	(27,610)		(34,149)
Prepaid expenses	6,000		(200)
Due to outside management consultants	-	-	306,892
Accounts payable	91,319	88,226	122,406
Accrued interest	2,466	5,728	38,760
Net cash flows used in operating activities	(95,366)	(194,027)	(1,136,157)
<b>Cash Flows from Investing Activities</b>			



Edgar Filing: ProtoKinetix, Inc. - Form 10QSB/A

Purchase of computer equipment	-	-	(3,388)
Net cash flows used in investing activities	-	-	(3,388)
<b>Cash Flows from Financing Activities</b>			
Warrants exercised	-	240,000	705,000
Stock options exercised	-	10,500	100,500
Issuance of common stock and warrants for cash	450,000	85,750	470,250
Proceeds from (payments) convertible notes	-	(85,750)	315,000
Net cash flows provided by financing activities	450,000	250,500	1,590,750
Net change in cash	354,634	56,473	451,205
Cash, beginning of period	96,571	283,556	
Cash, end of period	\$ 451,205	\$ 340,029	\$ 451,205
Cash paid for interest	\$ -	\$ -	\$ -
Cash paid for income taxes	\$ -	\$ -	\$ -

**Supplementary information**

**- Non-cash Transactions:**

Common stock issuable for acquisition of intangible assets	-	-	934,000
Stock subscriptions received		-	330,000
Note payable converted to common stock			191,677

See Notes to Financial Statements

## NOTES TO FINANCIAL STATEMENTS

### Note 1. Organization and Significant Accounting Policies

#### Organization

ProtoKinetix, Incorporated (the "Company"), a development stage company, was incorporated under the laws of the State of Nevada on December 23, 1999. The Company is a medical research company whose mission is the advancement of human health care.

In 2003, the Company entered into an assignment of license agreement (the "Agreement") with BioKinetix, Inc., an Alberta, Canada, corporation. The Agreement provided the Company with an exclusive assignment of all of the rights (the "Rights") that BioKinetix possessed relating to two proprietary technologies that are being developed for the creation and commercialization of "superantibodies," an enhancement of antibody technology that makes ordinary antibodies much more lethal. In consideration, the Company's Board of Directors authorized the Company to issue 16,000,000 shares of its common stock to the shareholders of BioKinetix.

The Company is also currently researching the benefits and feasibility of proprietary synthesized Antifreeze Glycoproteins ("AFGP"). In preliminary studies, AFGP has demonstrated an ability to protect and preserve human cells at temperatures below freezing.

#### Interim Period Financial Statements

The interim period financial statements have been prepared by the Company pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (the "SEC"). Certain information and footnote disclosure normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted pursuant to such SEC rules and regulations. The interim period financial statements should be read together with the audited financial statements and accompanying notes included in the Company's audited financial statements for the years ended December 31, 2005 and 2004. In the opinion of the Company, the unaudited financial statements contained herein contain all adjustments (consisting of a normal recurring nature) necessary to present a fair statement of the results of the interim periods presented.

#### Stock Based Compensation

Prior to January 1, 2006, the Company accounted for stock-based awards under the intrinsic value method, which followed the recognition and measurement principles of APB Opinion No. 25, "Accounting for Stock Issued to Employees", and related Interpretations. The intrinsic value method of accounting resulted in compensation expense for stock options to the extent that the exercise prices were set below the fair market price of the Company's stock at the date of grant.

As of January 1, 2006, the Company adopted SFAS No. 123(R) using the modified prospective method, which requires measurement of compensation cost for all stock-based awards at fair value on the date of grant and recognition of compensation over the service period for awards expected to vest. The fair value of stock options is determined using the Black-Scholes valuation model, which is consistent with the Company's valuation techniques previously utilized for options in footnote disclosures required under SFAS No. 123, "Accounting for Stock Based Compensation", as amended by SFAS No. 148, "Accounting for Stock Based Compensation Transition and Disclosure".

Since the Company did not issue stock options to employees during the three months ended March 31, 2006 or 2005, there is no effect on net loss or earnings per share had the Company applied the fair value recognition provisions of SFAS No. 123(R) to stock-based employee compensation. When the Company issues shares of common stock to employees and others, the shares of common stock are valued based on the market price at the date the shares of common stock are approved for issuance.

#### Going Concern

As shown in the financial statements, the Company has not developed a commercially viable product, has not generated any revenues to date and has incurred losses since inception, resulting in a net accumulated deficit at March 31, 2006. These factors raise substantial doubt about the Company's ability to continue as a going concern.

The Company needs additional working capital to continue its medical research or to be successful in any future business activities and continue to pay its liabilities. Therefore, continuation of the Company as a going concern is dependent upon obtaining the additional working capital necessary to accomplish its objective. Management is presently engaged in seeking additional working capital.

The accompanying financial statements do not include any adjustments to the recorded assets or liabilities that might be necessary should the Company fail in any of the above objectives and is unable to operate for the coming year.

#### Earnings per Share

Basic loss per share is computed by dividing the net loss available to common shareholders by the weighted average number of common shares outstanding in the period. The Company's stock split 1:75 on August 24, 2001. In April 2002, the Board of Directors approved a 2.5 for 1 split of the Company's stock. The accompanying financial statements are presented on a post-split basis. The loss per share for the periods ended March 31, 2006 and 2005, have been adjusted accordingly. Diluted earnings per share takes into consideration common shares of outstanding (computed under basic earnings per share) and potentially dilutive securities. The effect of debt convertible into common shares was not included in the computation of diluted earnings per share for all periods presented because it was anti-dilutive due to the Company's losses. Common stock issuable is considered outstanding as of the original approval date for purposes of earnings per share computations.

#### Note 2. Restatement

During 2003 and 2004, the Company acquired license rights to proprietary medical research technologies, which were capitalized at the time of acquisition as intangible assets having indefinite lives. While the Company's management continues to believe the license rights are of probable future benefit to the Company in its continuing efforts to pursue the development of commercially viable products, it was appropriate for accounting purposes to expense the cost of the acquisition of the license rights. Accordingly, the accompanying financial statements have been restated to correct the error and recognize as expense the cost of those acquired license rights at the time of their acquisition.

During 2005, one of the acquired license rights was deemed to have had no remaining useful life and, accordingly, an impairment loss of \$269,756 was recognized. Because of the 2003 and 2004 restatements, this impairment expense is eliminated for 2005.

The effects of the restatement on the March 31, 2006 financial statements are as follows:

Intangible assets decreased by \$3,110,000 and the Accumulated Deficit increased by \$3,110,000

The effects of the restatement on the March 31, 2005 financial statements are as follows:

Intangible assets decreased by \$3,379,756 and the Accumulated Deficit increased by \$3,379,756.

The effect of the restatement on the March 31, 2006 amounts in the Cumulative During the Development Stage period are as follows:

Expenses, specifically Licenses, increased by \$3,379,756 to \$3,379,756, and the Impairment Loss of \$269,756 was eliminated, increasing total expenses by a net amount of \$3,110,000 to \$15,062,710. The Loss from Continuing Operations increased by \$3,110,000 to (\$15,060,710) and the Net Loss increased by \$3,110,000 to (\$15,104,176).

For purposes of the Statement of Cash Flows, the Net Loss for the Period increased to (\$15,104,176) and the Issuance of Common Stock for Services and Expenses increased by \$3,334,000 to \$11,604,141, and the Acquisition of Intangible Assets for \$45,756 was eliminated.

#### Note 3. Convertible Note Payable

On February 1, 2004, the Company executed a subscription agreement under which the Company issued to a corporation an 8% secured convertible note in exchange for \$315,000. The note is due February 1, 2006, and is convertible into shares of the Company's common stock at the lower of \$0.30 per share or 70% of the average of the three lowest trading prices for the 30 days prior to the conversion date. No beneficial conversion feature was applicable to this convertible note.

In March 2005, 285,832 common shares and in May 2005, 353,090 common shares were issued in lieu of payment on this note.

#### Note 4. Discontinued Operations

In 2003, the Company signed the licensing agreement described in Note 1. This agreement changed the Company's business plan to that of a medical research company. Accordingly, the operating results related to the Company's research prior to the licensing agreement have been presented as discontinued operations in these financial statements for all periods presented.

#### Note 5. Subsequent Events

On May 1, 2006 the company received a Notice of Conversion from the Convertible Note Holder to convert \$158,783.60 of principal and interest into 529,279 shares of common stock.